Explore the Power of
Experience digital transformation with our customized solutions designed to meet the specific needs of each client in the Pharma, Chemistry, and Biotech industries.
Generative Artificial Intelligence
Mission
Be a global reference in deeptech solutions by AI-driven innovation, transforming research and development, regulatory compliance and drug discovery actions in new and safer therapies to the patients.
AI-Powered Pharma
Be a strategic AI partner for pharmaceutical and biotech companies
Vision
Values
People and Collaboration
Ethics and Responsability
Knowledge and Innovation
Our services
At InsilicAll, we provide expert, tailored toxicology and advisory services to support the full lifecycle of your pharmaceutical products. Our dedicated team specializes in comprehensive non-clinical development, rigorous safety and risk assessments (including environmental, excipient, and impurity evaluations), and the precise derivation of safety exposure limits like PDE and OEL. We are committed to ensuring your compliance with global regulations, optimizing your drug development strategies, and accelerating your product's journey to market with safety and efficacy at the forefront. Partner with us for cost-effective, science-driven solutions tailored to your unique needs.
Nitrosamine Risk Assessment
Qualification of Non-Mutagenic Impurities
Potentially Mutagenic Impurities (PMIs)
Residual Solvents
Pharma Risk Assessment Services
Extractables & Leachables risk assessment
Qualification of Excipients
Elemental Impurities
In silico assessment
Permissible Daily Exposure (PDE)
Health-Based Exposure Limits (HBELs) Services
Occupational Exposure Limits (OEL/OEB)
Filling Data Gaps with Read-Across






















Our products
Discover our suite of AI-driven software solutions, expertly designed to help you navigate regulatory compliance, manage critical risks, and accelerate innovation across the pharmaceutical, cosmetic, supplement, and food industries.
AI-Driven Industrial Pharmacoinformatics Solutions designed for compliance with FDA 21 CFR Part 11 and ANVISA's RDC No. 658/2021
Software solution providing end-to-end nitrosamine risk management for the Pharmaceutical, Cosmetic, Supplement, and Food industries
Software solution providing AI-driven mutagenicity and carcinogenicity assessment, boosted with RAx & expert review, ensuring ICH M7 & 21 CFR Part 11










Software solution providing AI-driven pKa and Ionization states, HPLC retention times, logP/D, solubility property prediction, boosted with hybrid Quantum Mechanical & AI models
Software solution providing a standardized, AI-driven approach for impurity risk assessment and ICH M7 purge factor calculations for API synthesis
Software solution providing generative AI & polypharmacology-driven molecular, biological signatures, creating multi-biological profiles, bridging chemistry and biology for drug discovery insights


Predict degradation products with Generative AI, grounded in reaction evidence, for ANVISA RDC 964/2025 & ICH compliant forced degradation studies

















15
Dedicated Experts
300+
Successful R&D Projects
Trusted by
20+
Our Clients

































Functioning as a Field Application Scientist and Regulatory Expert, he performs toxicological risk assessments during the pre-clinical and clinical development of drugs, cosmetics, environmental, and agricultural products. He also possesses experience in business management, securing public and private funds, and facilitating public-private Biotechnology partnerships within LATAM


Paulo H. M. Palmeira
Meet the team
Co-founder and CEO
Field Application Scientist


Dr. Rodolpho C. Braga
Co-founder and CTO
AI-driven drug discovery, Regulatory Expert
Leveraging over 15 years of computational modeling expertise, he spearheads the development of InsilicAll's Ecosystem software suite. It includes seven proprietary solutions for predictive toxicology and drug discovery, validated according to FDA 21 CFR Part 11 / GAMP5 guidelines to ensure suitability for use inside pharma companies. His technical leadership has propelled over 150 successful projects with major pharma clients, employing advanced techniques like Generative AI and atomic simulation


Dr. Ronaldo Pedro
Head of Innovation R&D


Dr. Fabricio Vargas
Co-founder
Scientist
He is the founder and Principal Investigator of NanoBusiness, a solid-state chemistry company operational in Brazil since 2008 with over 90 clients. NanoBusiness is uniquely ISO/IEC 17025 accredited and licensed by Anvisa/ICH for polymorphism analysis, utilizing its 20-person team, in-house PXRD equipment, and partnerships (SisNANO/MCTI). Recently arrived in the UK, the company's expansion is supported by the Department for International Trade (DIT)
Organic chemist with large experience as researcher and business management in the RD&I area at chemical and pharmaceutical industries. Vargas comes to InsilicAll as Head of Innovation to supervise the integration of InsilicAll's AI technology, foster innovation and ensure toxicological compliance for customers. Vargas will head an interdisciplinary group, support global projects, and boost corporate impacts. His inclusion promotes its aim to use AI to transform R&D and deliver innovative solutions for the industry